Public Release:  A new therapeutic option for human hepatocyte cancer

World Journal of Gastroenterology

p53-impaired tumors may be particularly suitable to parvovirus H-1-induced therapy. Although the p53 deficiency in tumors may induce resistance to chemotherapeutic agents, this will not affect the tumor cell susceptibility to H-1 PV-induced oncolytic infections. The parvovirus H-1 may also overcome other tumor resistance mechanisms developed in these tumor entities. So H-1 PV is a suitable agent to circumvent the resistance of p53-negative human hepatocellular carcinoma (HCC) cells to genotoxic agents, and enhances the apoptotic process which is dependent on functional PML. Thus, H-1 PV may be considered as therapeutic options for HCC, especially for p53-negative tumors.

The research team led by Prof. Markus Moehler from First Department of Internal Medicine of Johannes Gutenberg University of Mainz evaluated the synergistic targeting and killing of human HCC cells lacking p53 by the oncolytic autonomous PV H-1 with chemotherapeutic agents. This was published on 28 June 2008, in the World Journal of Gastroenterology.

Their result shows that parvovirus H-1 PV triggers an apoptotic type of death in human HCC cells, and that p53 is dispensable for this process. In contrast, PML, which is induced by H-1 PV infection, helps the parvovirus to kill the carcinoma cells, irrespective of their p53 status. Given the known dependence of apoptosis induction by radio-chemotherapeutic agents on the p53 status of target cells, parvoviruses appear to be suitable adjuvants to eliminate tumor cell populations with resistance against these agents by means of combined treatments. Parvovirus H-1 will be a new option for patients with human HCC and clinical phase I-II trials with these oncolytic gene therapy vectors should be done in the near future.

Many viruses are known to be pathogenic and increase carcinogenesis. In the contrary, the autonomous parvoviruses destroy tumors, activate the immune system and may thus even be good for the health of men.

###

Reference: Sieben M, Herzer K, Zeidler M, Heinrichs V, Leuchs B, Schuler M, Cornelis JJ, Galle PR, Rommelaere J, Moehler M. Killing of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires PML. World J Gastroenterol 2008; 14(24): 3819-3828

http://www.wjgnet.com/1007-9327/14/3819.asp

Correspondence to: Markus Moehler, First Department of Internal Medicine of Johannes Gutenberg University of Mainz, Langenbeckstrasse 1, Mainz 55101, Germany. moehler@mail.uni-mainz.de
Telephone: +49-6131-176839 Fax: +49-6131-176621

About World Journal of Gastroenterology

World Journal of Gastroenterology (WJG), a leading international journal in gastroenterology and hepatology, has established a reputation for publishing first class research on esophageal cancer, gastric cancer, liver cancer, viral hepatitis, colorectal cancer, and H pylori infection and provides a forum for both clinicians and scientists. WJG has been indexed and abstracted in Current Contents/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch) and Journal Citation Reports/Science Edition, Index Medicus, MEDLINE and PubMed, Chemical Abstracts, EMBASE/Excerpta Medica, Abstracts Journals, Nature Clinical Practice Gastroenterology and Hepatology, CAB Abstracts and Global Health. ISI JCR 2003-2000 IF: 3.318, 2.532, 1.445 and 0.993. WJG is a weekly journal published by WJG Press. The publication dates are the 7th, 14th, 21st, and 28th day of every month. WJG is supported by The National Natural Science Foundation of China, No. 30224801 and No. 30424812, and was founded with the name of China National Journal of New Gastroenterology on October 1, 1995, and renamed WJG on January 25, 1998.

About The WJG Press

The WJG Press mainly publishes World Journal of Gastroenterology.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.